ThermoGenesis's FDA-cleared pro-healing cell tech to hit US later this year
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for the Res-Q 60 system developed by stem cell specialist ThermoGenesis. The technology may now be used to prepare autologous platelet-rich plasma (PRP) from a patient's blood sample at the point of care. The PRP, a source of growth factors which has been shown to enhance healing, is mixed with autograft and/or allograft bone prior to application to a bone defect. The Rancho Cordova, California company says it hopes to form US distribution agreements "in the coming months", and begin selling Res-Q 60 later this year. The firm says that PRP is also potentially applicable to other conditions, including orthopaedic and cardiovascular indications.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.